OTCMKTS:KAYS

Kaya Competitors

$0.44
0.00 (-1.09 %)
(As of 04/9/2021 03:42 PM ET)
Add
Compare
Today's Range
$0.44
Now: $0.44
$0.49
50-Day Range
$0.40
MA: $0.48
$0.59
52-Week Range
$0.18
Now: $0.44
$0.99
Volume17,360 shs
Average Volume36,665 shs
Market Capitalization$6.28 million
P/E RatioN/A
Dividend YieldN/A
Beta0.28

Competitors

Kaya (OTCMKTS:KAYS) Vs. PVCT, PXSLY, SOAN, SXTC, MATN, and BNTC

Should you be buying KAYS stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Kaya, including Provectus Biopharmaceuticals (PVCT), Pharmaxis (PXSLY), AngioSoma (SOAN), China SXT Pharmaceuticals (SXTC), Mateon Therapeutics (MATN), and Benitec Biopharma (BNTC).

Provectus Biopharmaceuticals (OTCMKTS:PVCT) and Kaya (OTCMKTS:KAYS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Profitability

This table compares Provectus Biopharmaceuticals and Kaya's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Provectus BiopharmaceuticalsN/AN/A-478.82%
Kaya-1,558.07%N/A-586.93%

Institutional and Insider Ownership

0.1% of Provectus Biopharmaceuticals shares are held by institutional investors. 4.5% of Provectus Biopharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Provectus Biopharmaceuticals and Kaya's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Provectus BiopharmaceuticalsN/AN/A$-6,920,000.00N/AN/A
Kaya$1.01 million6.21$7.80 millionN/AN/A

Kaya has higher revenue and earnings than Provectus Biopharmaceuticals.

Analyst Recommendations

This is a summary of current ratings and target prices for Provectus Biopharmaceuticals and Kaya, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Provectus Biopharmaceuticals0000N/A
Kaya01002.00

Volatility & Risk

Provectus Biopharmaceuticals has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500. Comparatively, Kaya has a beta of 0.28, meaning that its share price is 72% less volatile than the S&P 500.

Summary

Provectus Biopharmaceuticals beats Kaya on 5 of the 7 factors compared between the two stocks.

Kaya (OTCMKTS:KAYS) and Pharmaxis (OTCMKTS:PXSLY) are both small-cap consumer discretionary companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

Analyst Ratings

This is a summary of current ratings and recommmendations for Kaya and Pharmaxis, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kaya01002.00
Pharmaxis0000N/A

Profitability

This table compares Kaya and Pharmaxis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kaya-1,558.07%N/A-586.93%
PharmaxisN/AN/AN/A

Volatility & Risk

Kaya has a beta of 0.28, meaning that its share price is 72% less volatile than the S&P 500. Comparatively, Pharmaxis has a beta of 1.15, meaning that its share price is 15% more volatile than the S&P 500.

Valuation & Earnings

This table compares Kaya and Pharmaxis' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kaya$1.01 million6.21$7.80 millionN/AN/A
Pharmaxis$8.75 million3.02$-9,360,000.00N/AN/A

Kaya has higher earnings, but lower revenue than Pharmaxis.

Summary

Pharmaxis beats Kaya on 4 of the 6 factors compared between the two stocks.

Kaya (OTCMKTS:KAYS) and AngioSoma (OTCMKTS:SOAN) are both small-cap consumer discretionary companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

Volatility & Risk

Kaya has a beta of 0.28, meaning that its share price is 72% less volatile than the S&P 500. Comparatively, AngioSoma has a beta of -0.31, meaning that its share price is 131% less volatile than the S&P 500.

Profitability

This table compares Kaya and AngioSoma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kaya-1,558.07%N/A-586.93%
AngioSomaN/AN/A-612.70%

Valuation & Earnings

This table compares Kaya and AngioSoma's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kaya$1.01 million6.21$7.80 millionN/AN/A
AngioSomaN/AN/A$-540,000.00N/AN/A

Kaya has higher revenue and earnings than AngioSoma.

Analyst Ratings

This is a summary of current ratings and recommmendations for Kaya and AngioSoma, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kaya01002.00
AngioSoma0000N/A

Summary

Kaya beats AngioSoma on 4 of the 5 factors compared between the two stocks.

Kaya (OTCMKTS:KAYS) and China SXT Pharmaceuticals (NASDAQ:SXTC) are both small-cap consumer discretionary companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, valuation, dividends, risk and profitability.

Risk & Volatility

Kaya has a beta of 0.28, indicating that its stock price is 72% less volatile than the S&P 500. Comparatively, China SXT Pharmaceuticals has a beta of 0.27, indicating that its stock price is 73% less volatile than the S&P 500.

Profitability

This table compares Kaya and China SXT Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kaya-1,558.07%N/A-586.93%
China SXT PharmaceuticalsN/AN/AN/A

Valuation and Earnings

This table compares Kaya and China SXT Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kaya$1.01 million6.21$7.80 millionN/AN/A
China SXT Pharmaceuticals$5.16 million4.84$-10,290,000.00N/AN/A

Kaya has higher earnings, but lower revenue than China SXT Pharmaceuticals.

Insider and Institutional Ownership

8.9% of China SXT Pharmaceuticals shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations for Kaya and China SXT Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kaya01002.00
China SXT Pharmaceuticals0000N/A

Summary

China SXT Pharmaceuticals beats Kaya on 4 of the 7 factors compared between the two stocks.

Mateon Therapeutics (OTCMKTS:MATN) and Kaya (OTCMKTS:KAYS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations.

Institutional and Insider Ownership

0.0% of Mateon Therapeutics shares are owned by institutional investors. 39.2% of Mateon Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings for Mateon Therapeutics and Kaya, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Mateon Therapeutics00103.00
Kaya01002.00

Mateon Therapeutics currently has a consensus price target of $3.00, suggesting a potential upside of 1,011.11%. Given Mateon Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Mateon Therapeutics is more favorable than Kaya.

Profitability

This table compares Mateon Therapeutics and Kaya's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Mateon TherapeuticsN/A-64.66%-42.92%
Kaya-1,558.07%N/A-586.93%

Valuation & Earnings

This table compares Mateon Therapeutics and Kaya's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mateon TherapeuticsN/AN/A$-6,640,000.00N/AN/A
Kaya$1.01 million6.21$7.80 millionN/AN/A

Kaya has higher revenue and earnings than Mateon Therapeutics.

Volatility & Risk

Mateon Therapeutics has a beta of 1.52, indicating that its share price is 52% more volatile than the S&P 500. Comparatively, Kaya has a beta of 0.28, indicating that its share price is 72% less volatile than the S&P 500.

Summary

Mateon Therapeutics beats Kaya on 8 of the 11 factors compared between the two stocks.

Benitec Biopharma (NASDAQ:BNTC) and Kaya (OTCMKTS:KAYS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, valuation, profitability and analyst recommendations.

Profitability

This table compares Benitec Biopharma and Kaya's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Benitec BiopharmaN/AN/AN/A
Kaya-1,558.07%N/A-586.93%

Analyst Recommendations

This is a summary of current recommendations and price targets for Benitec Biopharma and Kaya, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Benitec Biopharma01002.00
Kaya01002.00

Benitec Biopharma presently has a consensus price target of $14.00, indicating a potential upside of 181.69%. Given Benitec Biopharma's higher probable upside, research analysts plainly believe Benitec Biopharma is more favorable than Kaya.

Institutional & Insider Ownership

5.7% of Benitec Biopharma shares are held by institutional investors. 1.0% of Benitec Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Benitec Biopharma and Kaya's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Benitec Biopharma$100,000.00239.45$-8,270,000.00($8.10)-0.61
Kaya$1.01 million6.21$7.80 millionN/AN/A

Kaya has higher revenue and earnings than Benitec Biopharma.

Risk and Volatility

Benitec Biopharma has a beta of 1.84, indicating that its stock price is 84% more volatile than the S&P 500. Comparatively, Kaya has a beta of 0.28, indicating that its stock price is 72% less volatile than the S&P 500.

Summary

Benitec Biopharma beats Kaya on 7 of the 9 factors compared between the two stocks.


Kaya Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Provectus Biopharmaceuticals logo
PVCT
Provectus Biopharmaceuticals
0.6$0.07-0.0%$26.88 millionN/A0.00Gap Down
Pharmaxis logo
PXSLY
Pharmaxis
0.6$1.00-0.0%$26.39 million$8.75 million0.00
SOAN
AngioSoma
1.0$0.05-7.7%$26.16 millionN/A0.00News Coverage
Gap Up
SXTC
China SXT Pharmaceuticals
0.4$1.61-1.2%$24.98 million$5.16 million0.00
Mateon Therapeutics logo
MATN
Mateon Therapeutics
1.5$0.27-11.1%$24.37 millionN/A0.00
Benitec Biopharma logo
BNTC
Benitec Biopharma
1.2$4.97-1.0%$23.95 million$100,000.00-0.61Gap Up
Artelo Biosciences logo
ARTL
Artelo Biosciences
1.2$1.52-3.9%$23.88 millionN/A-1.50Upcoming Earnings
Q BioMed logo
QBIO
Q BioMed
0.5$0.92-0.5%$23.78 millionN/A-1.41Upcoming Earnings
AMAR
Amarillo Biosciences
0.5$0.51-18.6%$22.30 million$10,000.000.00Gap Down
Millendo Therapeutics logo
MLND
Millendo Therapeutics
1.5$1.16-4.3%$22.09 millionN/A-0.48Gap Down
NTN Buzztime logo
NTN
NTN Buzztime
0.4$6.43-20.1%$19.14 million$19.81 million-3.12High Trading Volume
Gap Up
Xenetic Biosciences logo
XBIO
Xenetic Biosciences
1.5$2.17-0.5%$18.98 million$20,000.000.00
Bellicum Pharmaceuticals logo
BLCM
Bellicum Pharmaceuticals
1.3$3.59-5.0%$18.17 million$7.14 million-0.27News Coverage
Gap Down
Bioxytran logo
BIXT
Bioxytran
0.0$0.18-5.6%$18.12 millionN/A0.00
Sonoma Pharmaceuticals logo
SNOA
Sonoma Pharmaceuticals
0.5$8.59-0.1%$17.84 million$18.94 million-9.65
XTLB
XTL Biopharmaceuticals
0.6$3.28-2.4%$16.86 millionN/A-5.29
NMUS
Nemus Bioscience
0.6$0.12-0.0%$16.07 millionN/A0.00High Trading Volume
Eledon Pharmaceuticals logo
ELDN
Eledon Pharmaceuticals
1.6$11.13-2.9%$15.98 millionN/A-0.50
Novus Therapeutics logo
NVUS
Novus Therapeutics
1.4$11.13-2.9%$15.98 millionN/A-0.50
Intec Pharma logo
NTEC
Intec Pharma
1.4$4.26-2.1%$15.30 millionN/A-0.60
BetterLife Pharma logo
BETRF
BetterLife Pharma
0.0$0.81-0.2%$13.91 millionN/A-1.08
NRIFF
Nuvo Pharmaceuticals
0.7$1.21-0.0%$13.79 million$52.41 million30.25
NVLNF
Novelion Therapeutics
0.6$0.70-1.2%$13.77 million$130.43 million0.00Gap Down
Teligent logo
TLGT
Teligent
1.2$0.62-0.0%$13.46 million$65.90 million-0.07
MedAvail logo
MDVL
MedAvail
1.8$12.99-0.2%$13.20 million$1.03 million-3.18Analyst Downgrade
News Coverage
Medicure logo
MCUJF
Medicure
0.6$1.28-5.1%$13.12 million$15.20 million-1.02Gap Down
CannaPharmaRX logo
CPMD
CannaPharmaRX
0.3$0.24-0.5%$12.54 millionN/A-0.47
CannaPharmaRX logo
CPMD
CannaPharmaRX
0.3$0.24-0.5%$12.54 millionN/A-0.47
iCo Therapeutics logo
ICOTF
iCo Therapeutics
0.5$0.08-0.0%$11.99 millionN/A-3.90
Nexien BioPharma logo
NXEN
Nexien BioPharma
0.0$0.20-2.4%$11.16 millionN/A0.00
TOWTF
Tower One Wireless
0.0$0.12-0.5%$11.06 million$4.08 million-1.33
Acerus Pharmaceuticals logo
TRLPF
Acerus Pharmaceuticals
0.5$0.04-23.6%$10.94 million$7.38 million0.00
Peak Pharmaceuticals logo
PKPH
Peak Pharmaceuticals
0.7$0.14-0.0%$10.59 millionN/A0.00News Coverage
GlobeImmune logo
GBIM
GlobeImmune
0.5$1.40-19.3%$9.60 millionN/A0.00
WHCA
Williston
0.0$0.70-0.0%$9.51 millionN/A0.00
ULUR
ULURU
0.3$0.28-0.0%$8.17 millionN/A0.00News Coverage
Acura Pharmaceuticals logo
ACUR
Acura Pharmaceuticals
0.6$0.34-0.0%$7.52 million$2.66 million-11.33Gap Up
Parnell Pharmaceuticals logo
PARNF
Parnell Pharmaceuticals
0.5$0.36-0.0%$7.20 millionN/A0.00
Pivotal Therapeutics logo
PVTTF
Pivotal Therapeutics
0.6$0.08-0.0%$7.15 millionN/A0.00
Intellipharmaceutics International logo
IPCIF
Intellipharmaceutics International
0.6$0.24-12.8%$5.57 million$3.48 million-1.96Gap Up
International Stem Cell logo
ISCO
International Stem Cell
0.8$0.73-0.0%$5.50 million$9.47 million0.00Gap Up
BCTXF
BriaCell Therapeutics
0.0N/AN/A$4.59 millionN/A-0.01
Wellness Center USA logo
WCUI
Wellness Center USA
0.5$0.04-30.6%$4.56 million$30,000.000.00News Coverage
Gap Up
American Bio Medica logo
ABMC
American Bio Medica
0.5$0.11-0.0%$4.38 million$3.65 million0.00Gap Up
AMBS
Amarantus BioScience
0.0$0.01-0.0%$4.37 millionN/A0.00Gap Up
FutureWorld logo
FWDG
FutureWorld
0.5$0.00-0.0%$3.80 millionN/A0.00Gap Up
AKRXQ
Akorn
0.1$0.03-0.0%$3.60 million$682.43 million-0.01
VGLS
VG Life Sciences
0.0$0.01-2.7%$3.50 millionN/A0.00Gap Down
Boston Therapeutics logo
BTHE
Boston Therapeutics
0.5$0.03-3.7%$3.00 million$20,000.00-1.35News Coverage
Gap Up
INNVD
Innovus Pharmaceuticals
0.6N/AN/A$2.90 million$23.99 million-0.72Gap Down
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.